Eleven-year retrospective survey of candidaemia in a university hospital in southwestern Greece

Clinical Microbiology and Infection

Volumn 16, Issue 9, 2010, Pages 1378-1381

  Spiliopoulou, A ^a   Vamvakopoulou, S ^a   Bartzavali, C ^a   Dimitracopoulos, G ^a   Anastassiou, E D ^a   Christofidou, M ^a  

^a UNIVERSITY OF PATRAS   (Greece)

Author keywords

Antifungals; Candida albicans; Candidaemia; Epidemiology; Non albicans Candida

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; POSACONAZOLE; PYRROLE DERIVATIVE; VORICONAZOLE;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BLOOD CULTURE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; FUNGAL STRAIN; FUNGAL VIRULENCE; FUNGUS CULTURE; FUNGUS ISOLATION; GREECE; HUMAN; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; NEWBORN INTENSIVE CARE; NONHUMAN; PRIORITY JOURNAL; UNIVERSITY HOSPITAL;

CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS;

EID: 77956112951     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2010.03193.x     Document Type: Article

References (24)

1. Peman J, Canton E, Gobernado M. Epidemiology and antifungal susceptibility of Candida species isolated from blood: results of a 2-year multicentre study in Spain. Eur J Clin Microbiol Infect Dis 2005, 24:23-30. Spanish ECMM Working Group on Candidaemia
2. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999, 29:239-244.
3. Bassetti M, Righi E, Costa A. Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis 2006, 6:-29.
4. Viscoli C, Girmenia C, Marinus A. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999, 28:1071-1079.
5. Reference method for broth dilution antifungal susceptibility testing of yeasts; Approved Standard 2002, Clinical and Laboratory Standards Institute, 2nd edn, CLSI Document M27-A2, CLSI: Wayne, PA
6. Ghannoum MA, Chen A, Buhari M. Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit. Clin Microbiol Infect 2009, 15:274-279.
7. Asadzadeh M, Al-Sweih NA, Ahmad S, Khan ZU. Antifungal susceptibility of clinical Candida parapsilosis isolates in Kuwait. Mycoses 2008, 51:318-323.
8. Araujo R, Costa-de-Oliveira S, Coutinho I, Rodrigues AG, Pina-Vaz C. Evaluating the resistance to posaconazole by E-test and CLSI broth microdilution methodologies of Candida spp. and pathogenic moulds. Eur J Clin Microbiol Infect Dis 2009, 28:1137-1140.
9. Metwally L, Walker MJ, Coyle PV. Trends in candidemia and antifungal susceptibility in a university hospital in Northern Ireland 2001-2006. J Infect 2007, 55:174-178.
10. Arendrup MC, Fuursted K, Gahrn-Hansen B. Seminational surveillance of fungemia in Denmark: notably high rates of isolates with reduced azole susceptibility. J Clin Microbiol 2005, 43:4434-4440.
11. Sendid B, Cotteau A, Francois N. Candidaemia and antifungal therapy in a French university hospital: rough trends over a decade and possible links. BMC Infect Dis 2006, 6:-88.
12. Horn DL, Neofytos D, Anaissie EJ. Epidemiology and outcomes of candidemia in 2019 patients: data from the Prospective Antifungal Therapy Alliance Registry. Clin Infect Dis 2009, 48:1695-1703.
13. Takakura S, Fujihara N, Saito T. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin. J Antimicrob Chemother 2004, 53:283-289.
14. Mokaddas EM, Al-Sweih NA, Khan ZU. Species distribution and antifungal susceptibility of Candida bloodstream isolates in Kuwait: a 10-year study. J Med Microbiol 2007, 56:255-259.
15. Presterl E, Daxbock F, Graninger W, Willinger B. Changing pattern of candidaemia 2001-2006 and use of antifungal therapy at the University of Vienna, Austria. Clin Microbiol Infect 2007, 13:1072-1076.
16. Diekema DJ, Messer SA, Brueggemann AB. Epidemiology of candidemia: 3-year results from the Emerging Infections and the Epidemiology of Iowa Organisms Study. J Clin Microbiol 2002, 40:1298-1302.
17. Lagrou K, Verhaegen J, Peetermans WE, De Rijdt T, Maertens J, Van Wijngaerden E. Fungemia at a tertiary care hospital: incidence, therapy, and distribution and antifungal susceptibility of causative species. Eur J Clin Microbiol Infect Dis 2007, 26:541-547.
18. Pasqualotto AC, Nedel WL, Machato TS, Severo LC. Risk factors and outcome for nosocomial breakthrough candidaemia. J Infect 2006, 52:216-222.
19. Dimopoulos G, Velegraki A, Falagas ME. A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece. Antimicrob Agents Chemother 2009, 53:1242-1244.
20. Tortorano AM, Peman J, Bernhardt H. Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 2004, 23:317-322.
21. Goldani LZ, Mario PS. Candida tropicalis fungemia in a tertiary care hospital. J Infect 2003, 46:155-160.
22. Leroy O, Gangneux JP, Montravers P. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit Care Med 2009, 37:1612-1618.
23. Krcmery V, Barnes AJ. Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance. J Hosp Infect 2002, 50:243-260.
24. Pappas PG, Kauffman CA, Andes D. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:503-535.